8-K
filed June 1, 2026, 7:30 AM ET
ticker HCWB
CIK 0001828673
other material
confidence high
sentiment neutral
materiality 0.60
Nasdaq panel grants HCW Biologics extension to July 29, 2026 to regain $1 bid price compliance
HCW Biologics Inc.
- Must demonstrate bid price at or above $1 for 20 consecutive trading days by July 29, 2026.
- If deficient before September 22, 2026, Company will be immediately delisted.
- Non-compliance with any other listing rule before Sep 22 gives 7 days to advise panel.
- Regaining compliance will result in a Discretionary Panel Monitor for one year.
- Company's hearing was on May 5, 2026; panel granted extension on May 29, 2026.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001493152-26-026529
- form_type
- 8-K
- ticker
- HCWB
- cik
- 0001828673
- company_name
- HCW Biologics Inc.
- filed_at
- 2026-06-01T11:30:18+00:00
- discovered_at
- 2026-06-01T11:35:00.280250+00:00
- generated_at
- 2026-06-01T11:35:44.012401+00:00
- sec_items
- ["3.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001493152-26-026529
- json_url
- https://secwatch.observer/filing/0001493152-26-026529.json
- markdown_url
- https://secwatch.observer/filing/0001493152-26-026529.md
- text_url
- https://secwatch.observer/filing/0001493152-26-026529.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/0001493152-26-026529-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/form8-k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same SEC item: 3.01
same event type: other_material
similar materiality
Filing page
SEC filing
CCLD
CareCloud completes full redemption of Series B Preferred Stock for ~$41.6M
CareCloud, Inc.
May 15, 2026, 5:00 PM ET
other_material
Items 3.01, 8.01, 9.01
same SEC item: 3.01
same event type: other_material
similar materiality
Filing page
SEC filing
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same SEC item: 3.01
same event type: other_material
similar materiality
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same SEC item: 3.01
same event type: other_material
similar materiality
Filing page
SEC filing
CUK
Carnival completes DLC unification and redomiciliation to Bermuda; Carnival plc now a subsidiary
CARNIVAL PLC
May 7, 2026, 7:59 PM ET
other_material
Items 1.02, 2.01, 3.01, 3.02, 3.03, 5.01, 5.03, 7.01, 9.01
same SEC item: 3.01
same event type: other_material
similar materiality
Filing page
SEC filing
ADTX
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Aditxt, Inc.
May 29, 2026, 4:21 PM ET
other_material
Items 3.01, 9.01
same SEC item: 3.01
same event type: other_material
Filing page
SEC filing
LIMN
Liminatus Pharma receives Nasdaq delisting notice; appeals filed
Liminatus Pharma, Inc.
May 27, 2026, 4:30 PM ET
other_material
Items 3.01, 9.01
same SEC item: 3.01
same event type: other_material
Filing page
SEC filing
EMAT
Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved
Evolution Metals & Technologies Corp.
May 26, 2026, 5:28 PM ET
other_material
Items 3.01, 7.01, 9.01
same SEC item: 3.01
same event type: other_material
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.